Patient characteristics (n = 123)
| Variable . | Category . | Median (range) or no. (%) . |
|---|---|---|
| Age, y | 56 (21-83) | |
| Sex | Female | 68 (55) |
| CML duration, months | 67 (2-268) | |
| Performance Status | > 1 | 29/118 (24) |
| Splenomegaly | Yes | 7 (6) |
| Prior interferon therapy | Yes | 70 (57) |
| Peripheral blood | Leukocytes, × 109/L | 11.5 (1.8-160.8) |
| Hemoglobin, g/dL | 12.3 (7.7-16.6) | |
| Platelets, × 109/L | 306 (103-1436) | |
| Blasts, % | 0 (0-14) | |
| Basophils, % | 2 (0-17) | |
| Bone marrow | Blasts, % | 2 (0-12) |
| Basophils, % | 2 (0-14) | |
| Best response to imatinib | Cytogentic response | 77 (63) |
| Complete | 34 (28) | |
| Partial | 21 (17) | |
| Minor | 22 (18) | |
| Complete hematologic response only | 30 (24) | |
| Intolerant | 8 (7) | |
| Resistant/unknown | 2 (2)/6 (5) | |
| Second TKI therapy | Dasatinib | 78 (63) |
| Nilotinib | 45 (37) | |
| Active disease at the start of second TKI | Yes | 84 (68) |
| Clonal evolution | Yes | 28 (23) |
| > 90% Philadelphia positivity | Yes | 82/117 (70) |
| Mutation | None | 42 (34) |
| Low IC50 | 23 (19) | |
| Intermediate IC50 | 12 (10) | |
| Not done | 43 (35) |
| Variable . | Category . | Median (range) or no. (%) . |
|---|---|---|
| Age, y | 56 (21-83) | |
| Sex | Female | 68 (55) |
| CML duration, months | 67 (2-268) | |
| Performance Status | > 1 | 29/118 (24) |
| Splenomegaly | Yes | 7 (6) |
| Prior interferon therapy | Yes | 70 (57) |
| Peripheral blood | Leukocytes, × 109/L | 11.5 (1.8-160.8) |
| Hemoglobin, g/dL | 12.3 (7.7-16.6) | |
| Platelets, × 109/L | 306 (103-1436) | |
| Blasts, % | 0 (0-14) | |
| Basophils, % | 2 (0-17) | |
| Bone marrow | Blasts, % | 2 (0-12) |
| Basophils, % | 2 (0-14) | |
| Best response to imatinib | Cytogentic response | 77 (63) |
| Complete | 34 (28) | |
| Partial | 21 (17) | |
| Minor | 22 (18) | |
| Complete hematologic response only | 30 (24) | |
| Intolerant | 8 (7) | |
| Resistant/unknown | 2 (2)/6 (5) | |
| Second TKI therapy | Dasatinib | 78 (63) |
| Nilotinib | 45 (37) | |
| Active disease at the start of second TKI | Yes | 84 (68) |
| Clonal evolution | Yes | 28 (23) |
| > 90% Philadelphia positivity | Yes | 82/117 (70) |
| Mutation | None | 42 (34) |
| Low IC50 | 23 (19) | |
| Intermediate IC50 | 12 (10) | |
| Not done | 43 (35) |